Short answer: once Entresto’s patent protections expire in a given market, generic competition is likely to enter and put downward pressure on prices. The size and timing of the effect depend on the specific patent/exclusivity status in that market, and on how many generic competitors there are.
Key factors that will shape the price change
- Patent and exclusivity status
- If the last composition-of-matter or key use patents expire and there are no blocking patents or regulatory exclusivities, generics can enter.
- If there are still pediatric exclusivity or other regulatory protections, entry can be delayed.
- Some markets have additional patent-type protections or market exclusivities that extend protection beyond the initial expiry date.
- Regulatory pathway for generics
- In many jurisdictions, generic versions must obtain approval based on the brand’s data; exclusivities or data protection can slow that process.
- Competition level
- The number of generic manufacturers entering the market determines how quickly and how far prices fall. More competition usually means steeper price declines.
- Payer, formularies, and rebates
- Payer negotiations, rebates, and formulary placement influence actual prices seen by patients, sometimes blunting or accelerating the real-world price drop.
- Market-specific dynamics
- Pricing, insurance dynamics, and access programs vary by country, so the magnitude of price change can differ widely between regions (e.g., US vs EU vs other regions).
What this typically looks like after expiry (general pattern)
- First wave of generics enters: substantial price reduction for the branded product and for the first generic(s).
- After additional generics arrive: further declines, with the market converging to a much lower price point than the pre-expiry brand price.
- Brand price may still be present at some level due to rebates, patient assistance, or formulary protections, but the majority of sales tend to shift toward generics over time.
Region-specific notes (high level)
- United States: Generics often enter within a year or two after expiry (subject to patent litigation outcomes). The price gap between brand and generics tends to be large, and payers actively manage rebates and formulary placements.
- Europe: Similar dynamics, but the exact timing and price impact depend on each country’s patent status, national pricing and reimbursement rules, and the number of competing generics.
- Other regions: The pattern is similar, but the timing and extent of price drops can vary based on local patent challenges, regulatory paths, and affordability programs.
What you can do if you want specifics
- Check current patent status and expiry dates for Entresto in your market (and any active litigation or exclusivity provisions) via the official patent/brand databases:
- United States: FDA/Orange Book and USPTO Patent Center
- Europe: European Patent Office and national health authorities
- Look for announcements about generic approvals and launches in your region.
- Review payer formularies and recent price data for Entresto and its generics to gauge real-world pricing and out-of-pocket costs.
Would you like region-specific details (US, EU, or another country) and I can outline the current patent/exclusivity situation and what to expect for that market?